$AMGN

Amgen and Merck offer 3% dividend yields while successfully managing patent cliffs through diversified pipelines and new product approvals.

Accumulus launches Veeva RIM integration enabling real-time regulatory submissions. Amgen early adopter reports significant time savings and operational improvements.

Accumulus Technologies unveiled Direct Connect for Veeva RIM, enabling real-time integration between regulatory systems and health authorities, reducing manual work for life sciences companies.

Apple's strong Q2 earnings powered U.S. equities to all-time highs Friday, with S&P 500 and Nasdaq 100 advancing on broad tech rally, though energy declined.

FDA launches real-time clinical trial initiative with $AMGN and $AZN pilots, aiming to accelerate drug approvals and eliminate traditional reporting delays.

S&P 500 hits record highs with 84% earnings beats and 15.1% growth, as Magnificent Seven tech giants report this week and Fed meets on rates.

Over 65 pharma companies advance 75+ COPD drugs, shifting from traditional bronchodilators to targeted biologics as AstraZeneca's tozorakimab validates new approaches.

Kopp Family Office exits $3.5M Viridian stake as stock plummets 50% following disappointing Phase 3 data and Amgen's superior competing results.

Bispecific antibody drug conjugates market projected at $2B+ by 2030, with first approval expected by 2028 amid 150+ global clinical trials.

Bispecific antibody market projected to reach $60 billion by 2031 from $16 billion in 2025, with 550+ clinical trials and 18 approved drugs driving sector transformation.

Sagimet Biosciences appoints Dr. Andreas Grauer as Chief Medical Officer, replacing retiring Dr. Eduardo Martins. Grauer joins from senior roles at Amgen and Corcept, receiving $1.34M in stock options.

US eosinophilic esophagitis market valued at $647M in 2025 projected to grow 13.2% annually through 2036, driven by novel drug classes and improved diagnostics.

Global atopic dermatitis market projected to grow from $10.8B in 2023 to $26.2B by 2033, driven by seven late-stage pipeline drugs and expanded treatment options.

Martin Capital Partners exits $4.5M Robert Half position as $RHI stock plunges 44.6% amid staffing sector weakness and cooling corporate hiring.

President Trump's executive order imposes 100% tariffs on imported drugs, exempting 13 companies with MFN agreements and U.S. manufacturing commitments through 2029.

Tech stocks tumble toward correction as investors shift to defensive healthcare dividends. AbbVie and Amgen offer stability through economic uncertainty.

U.S. stocks recovered from sharp morning losses on geopolitical concerns and Tesla's disappointing deliveries, finishing near breakeven. Oil surged 10% on Iran tensions.

Trump administration preparing 100% tariffs on pharmaceutical companies refusing pricing deals, with major drugmakers already securing three-year reprieves through MFN agreements.

Ardelyx appoints Dr. Rajani Dinavahi, veteran biotech executive from Amgen and Atara Biotherapeutics, as Chief Medical Officer to lead clinical strategy and pipeline advancement.

FDA warns of 76 drug-induced liver injury cases linked to Amgen's Tavneos, including 8 deaths and severe bile duct syndrome, raising significant safety and commercial concerns.